CVN293 is a selective inhibitor of the potassium channel KCNK13, with the advantages of brain permeability and oral bioavailability. It inhibits the production of the pro-inflammatory cytokine IL-1beta induced by NLRP3 in microglia and can be used for research into neurodegenerative diseases.